Page 2 - Biotech

US bill to restrict business with China's biotech companies passes House

The US Senate's Homeland Security committee voted in March to approve a similar bill

Concord Biotech shares hit all time high; Antique Broking reiterates 'Buy'

Antique Broking is bullish on Concord's business model, new launches and niche products

Merck Life Science partners with Aragen to boost biotech R&D in India

Merck Life Science will supply equipment and technologies to Aragen, facilitating a more efficient clinical-to-commercial process timeline

Lord's Mark Microbiotech set to launch saliva-based organ age test

The company claims this test will be priced between Rs 15,000 and 20,000, making it more affordable than the current market options, which range from Rs 30,000 to 40,000

Karnataka to triple its BioEconomy to $100 billion by 2030: Govt report

The report reveals that the number of startups in the state has surpassed 1,000, with a notable increase in biotech ventures

Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8%

Syngene International shares ended the day's trade on BSE at Rs 694.2 apiece, down one per cent

Biocon signs deal with Biomm SA to commercialise diabetes drug in Brazil

Biomm SA develops and commercialises complex biotech and biosimilar drug products

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...

Healthcare innovation to double at $60 bn opportunity by FY28 in India

Indian vaccines and biotech market, which was valued at $4 billion in FY23, accounting for 15 percent of the innovation market, has quickly grown from $1.2 billion in FY20

US rivalry with China expands to biotech, lawmakers see failure to compete

US lawmakers are raising alarms about what they see as America's failure to compete with China in biotechnology, warning of the risks to US national security and commercial interests. But as the two countries' rivalry expands into the biotech industry, some say that shutting out Chinese companies would only hurt the US. Biotechnology promises to revolutionise everyday life, with scientists and researchers using it to make rapid advances in medical treatment, genetic engineering in agriculture and novel biomaterials. Because of its potential, it has caught the attention of both the Chinese and US governments. Bills have been introduced in the House and Senate to bar foreign adversary biotech companies of concern from doing business with federally funded medical providers. The bills name four Chinese-owned companies. The Chinese Embassy said those behind the bills have an ideological bias and seek to suppress Chinese companies under false pretexts. It demanded that Chinese companies b

Falling biotech funding may be a bitter pill to swallow for CDMOs

Indian CDMOs are focusing on big biotech clients, and going forward, they believe the funding issues will not last long

Karnataka to unveil revised biotech policy: CM at Bengaluru Tech Summit

Karnataka Chief Minister Siddaramaiah on Wednesday said the government would unveil a revised biotech policy at the Bengaluru Tech Summit-2023, an annual global tech event which took off here. Speaking at the inauguration of the three-day BTS, Siddaramaiah also said the state is set to launch the Animation, Visual Effects, Gaming, Comics, and Extended Reality (AVGC-XR) policy. "As we continue to champion advancements in biotechnology, I am thrilled to announce that revised biotech policy is set to be unveiled at the Bangalore Tech Summit," the chief minister said. This policy revision reflects the Karnataka government's commitment to staying ahead of all and fostering growth in this critical sector, he added. Siddaramaiah said that recognising the evolving landscape technology and creativity, the Karnataka government understands the importance of animation, visual effects, gaming, and comics. "It gives me immense pleasure to share that the Government of Karnataka is set to launch

Pfizer enters talks to buy Seagen for over $30 billion, says report

Deal will help the firm add to its line-up of cancer treatments

Enzene Biosciences raises $50 million, aims to expand into global markets

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

Cough syrup deaths: Centre, UP team inspect pharma firm's Noida unit

Cough syrup maker linked to Uzbekistan deaths halts production; samples of Dok-1 Max sent for analysis

Shreehas Tambe elevated as MD & CEO of Biocon Biologics effective Monday

He was earlier the firm's deputy CEO; Outgoing MD Arun Chandavarkar to remain on co Board

World's most expensive drug approved to treat Hemophilia at $3.5 mn a dose

CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found

Biotech firm Bharat Serums & Vaccines working to reduce import dependence

Firm is develop recombinant products in hormones, eyes acquisitions in South East Asia

Mylab, firm that makes kits to detect Covid, starts pathology test facility

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

Biocon net profit rises 71% to Rs 144 cr in June quarter; revenue rises 23%

Biotechnology major Biocon on Wednesday reported a 71 per cent increase in consolidated net profit at Rs 144 crore for the June quarter on the back of robust growth across business verticals. The company had posted a net profit of Rs 84 crore in the April-June quarter of the previous fiscal. Total revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulatory filing. Biocon Executive Chairperson Kiran Mazumdar-Shaw said revenues grew as a result of robust growth in both biosimilar and generics verticals. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains," she added. All the company businesses are poised for the next phase of sustainable growth which has been challenged during the two years of the Covid pandemic, Mazumdar-Shaw said.